[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US3416530A - Eyeball medication dispensing tablet - Google Patents

Eyeball medication dispensing tablet Download PDF

Info

Publication number
US3416530A
US3416530A US531311A US53131166A US3416530A US 3416530 A US3416530 A US 3416530A US 531311 A US531311 A US 531311A US 53131166 A US53131166 A US 53131166A US 3416530 A US3416530 A US 3416530A
Authority
US
United States
Prior art keywords
eyeball
medicament
tablet
medication
medication dispensing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US531311A
Inventor
Richard A Ness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US531311A priority Critical patent/US3416530A/en
Application granted granted Critical
Publication of US3416530A publication Critical patent/US3416530A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Definitions

  • medication is applied to the cornea of the eye in liquid or ointment form.
  • the application of medication to the cornea should be substantially continuous.
  • the medication is applied at intervals during the day and night.
  • the difiiculty with such periodic application is that the eye receives a massive dose at the time of application, and shortly thereafter, substantially all of the medication is washed away by tears, leaving the eye, particularly the cornea thereof, without medication until the next dose is applied.
  • An important object of this invention is the provision of means whereby medication is applied to the eyeball continuously over an extended period of time.
  • Another object of this invention is the provision of a medication dispensing device which may be quickly and easily applied to the eyeball, which will dispense medication thereto-at a predetermined rate of speed, and which may be as quickly and easily removed and replaced when the supply of medicament is exhausted.
  • Still another object of this invention is the provision of a medication dispensing device having means providing a visual indication of the quantity of medicament available to the eyeball.
  • Yet another object of this invention is the provision of a medication dispensing device which will conform to the curvature of the sclera so as to fit comfortably in the culde-sac of the conjunctiva between the upper eyelid and the eyeball or globe in radially spaced relation to the cornea, and disposed in the path of tear flow to the cornea, whereby to be responsive to flow of tears to dispense medicament thereto.
  • I provide a medication dispensing tablet-like body of concavo-convex section and of flexible material and having a smooth curved outline, the concave inner surface of said body having a generally spherical radius conforming substantially to the radius of the scleral portion of an eyeball, the body containing a supply of medicament and adapted to dispense the medicament to tears during flow of said tears from the lacrimal gland toward the cornea of the eyeball, when the body is applied to the eyeball as set forth.
  • FIG. 1 is a view partly in front elevation and partly diagrammatic, of a human eye, illustrating the use of the invention
  • FIG. 2 is a view partly in vertical section and partly diagrammatic of an eyeball and the upper and lower eyelids associated therewith, showing the placement of the medication dispensing tablet of this invention
  • FIG. 3 is a view in top plan of a preferred form of medication dispensing tablet of this invention.
  • FIG. 4 is a longitudinal section, taken on the line 44 of FIG. 3;
  • FIG. 5 is a transverse section taken substantially on the line 5-5 of FIG. 3;
  • FIG. 6 is a view corresponding ot FIG. 3 but showing a modified form of tablet
  • FIG. 7 is a view in perspective of means for packaging the tablet of this invention.
  • FIG. 8 is an enlarged transverse section, taken on the line 88 of FIG. 7.
  • a human eye is shown, more or less diagrammatically, as comprising an eyeball 1, and upper and lower eyelids 2 and 3 respectively, the eyeball 1 being covered for the greater parts of its area by the sclera 4 and at its anterior portion by the cornea 5.
  • the eyelids 2 and 3 are lined with a epithelial membrane or conjunctiva 6 which covers the exposed portion of the eyeball including the cornea 5, that portion covering the cornea being transparent, that portion of the conjunctiva 6 which lines the upper eyelid 2 and the underlying portion of the sclera 4 defining a cul-de-sac 7.
  • Upper and lower eyelashes are indicated at 8 and 9 respectively.
  • FIGS. l-S a hollow tablet-like body 11, of concavoconvex cross section, is shown as comprising inner and outer walls 12 and 13 respectively, the walls 12 and 13 being joined at their marginal edge portions and defining a chamber 14 that is filled with medicament 15.
  • the marginal juncture of the walls 12 and 13 is rounded, as indicated at 16 in FIGS. 4 and 5, so as to avoid sharp edges and, in the preferred embodiment of the invention, the
  • FIGS. 1 and 3 outline of the body 11 is bean-shaped or reniform as shown in FIGS. 1 and 3. Communication between the chamber 14 and the exterior of the body 11 is had through a plurality of capillary openings 17 in the walls 12 and 13, as well as through the joined edges thereof.
  • the marginal edges of the inner and outer walls 12 and 13 may be joined together by any suitable means, such as heat-sealing, gluing or the like.
  • the capillary openings 17 are disposed in the areas of the walls 12 and 13 adjacent the marginal edges thereof as shown particularly in FIG. 3.
  • the overall dimensions of the body 11 are quite small.
  • the overall length of the body 11 is approximately fifteen millimeters, the width thereof intermediate its ends being in the neighborhood of eleven or twelve millimeters.
  • the outer surface 18, which is adapted to be disposed adjacent the sclera, of the inner wall 12 is generally spherical, having a spherical radius of approximately twelve millimeters, corresponding to the radius of the scleral portion of the eyeball.
  • the dimensions noted above may be varied in accordance with eyeballs of different sizes. It will be noted, with reference to FIGS.
  • the body 11 is of substantially greater thickness at its central portion than at the marginal edge thereof, whereby to define a chamber 14 of a :size to contain sufiicient highly concentrated medication for adequate treatment over at least a days time.
  • the maximum thickness of the body 11 is approximately one to one and one-half millimeters.
  • the tear liquid and medicament mixture will flow over the cornea 5 which absorbs the medicament, thus administering a constant supply of medicament to the cornea until the supply within the chamber 14 is exhausted.
  • the lacrimal gland is disposed just slightly above and posteriorly or rearwardly of the cul-de-sac 7 in a depression of the upper, outer wall of the orbit, not shown.
  • the flow of tears from the lacrimal gland 10 is generally diagonally across the cornea toward the puncta, as is wellknown to those skilled in this art, the general direction of tear flow being indicated by arrows in FIG. 1.
  • the tablet-like body 11 may be made from any suitable material that is flexible, biologically inert, nonellergenic, insoluble in tear liquid, and chemically compatible with the medicament in the chamber 14.
  • the walls 12 and 13 of the body 11 may be made from polyethylene or any other of well-known synthetic plastic materials having the above-mentioned characteristics.
  • the medicament in the chamber 14 comprises the desired medication for treatment and a soluble or semi-soluble carrier or matrix, the matrix being of any suitable substance such as gum acacia, gum tragacanth, or the like.
  • the matrix serves to hold the medication together during fabrication of the body 11, and operates as a diluent during the medication dispensing operation of the body 11.
  • Insertion of the body 11 into the cul-de-sac 7 and removal of the body 11 therefrom is a relatively simple and easy operation.
  • the body 11 may be mounted on or grasped by a suitable tool or holder, not shown, but which may include a minute suction cup for engaging the outer Wall of the body 11.
  • the upper eyelid is raised upwardly and outwardly adjacent the outer corner portion of the eye to open the cul-de-sac 7, and the body 11 inserted and released from the holder.
  • the holder may be one of several types commonly used to insert and remove present day corneal contact lenses, artificial eyes and the like.
  • the present invention contemplates the use of an indicator dye in the medicament 15 to serve as a visual indication as to the supply of medicament within the chamber 14.
  • an indicator dye for this purpose, a small amount of methylene blue or any suitable dye material is used. So that the medicament 15 may be easily seen, the outer wall 13 of the body 11 is preferably transparent, the inner wall 12 being preferably opaque and having a color in substantial contrast to the color of the medicament 15 or indicator dye.
  • the modified form of the invention illustrated in FIG. 6 comprises a body 19 that is generally elliptical in outline but which in all other respects is identical to the form of body 11 illustrated in FIGS. 1-5.
  • the parts of the body 19 shown in FIG. 6, corresponding to similar parts of the body 11, are indicated by corresponding reference numerals with prime marks added.
  • the outer wall 13 and the marginal edge 16' are provided with capillary openings 17' and it may be assumed that the body 19 is cross-sectionally similar to the body 11, as shown in FIGS. 4 and 5.
  • FIGS. 7 and 8 A preferred means for packaging the tablets of this invention is shown in FIGS. 7 and 8.
  • a relatively thick sheet-like base member 20 is shown as being formed to provide a plurality of upwardly opening pockets 21, each for reception of a different one of the tablets of bodies 11 or 19, and having upwardly dished bottom walls 22 which substantially fit the overlying inner wall-s of the bodies 11 or 19.
  • a relatively thin cover sheet 23 overlies the base member 20 and is releasably adhered to the top surface thereof intermediate the pockets 21 and adjacent the marginal edge of the base member 20.
  • the base member 20 and cover sheet 23 are made from synthetic plastic sheet material, the cover sheet 23 being preferably transparent so that occupancy of any of the pockets 21 by a tablet may be readily seen.
  • the upper surfaces of the base member 20 in the pockets 21 are corrugated, knurled, or otherwise roughened, as indicated at 21a, to prevent the liquid in the pockets 21 from causing the bodies 11 to adhere to the pockets 21, and to break any suction therebetween, which might occur if the surfaces of the pockets 21 were smooth.
  • the outline of the tablets 11 or 19 may be of any curved configuration, such as circular, if desired. Further, the capillary openings 17 and 17 need not be necessarily circular as shown.
  • the walls 12, 13, 12' and 13 may be made from porous material having the characteristics above described in connection with the body 11. Still further, this invention contemplates a body of the shape or shapes above described, which in itself is a solid body, as distinguished from the bodies 11 or 19 which define inner chambers, but which is in itself sufficiently porous to receive the desired amount of medicament and retain the same until the medicament is gradually leached therefrom under the action of tear flow.
  • the body not shown, may be made from suitable material of a given color, the medication being dyed to a contrasting color, whereby to provide an indication as to the presence or absence of medication in the porous body.
  • a medication dispensing tablet for a human eyeball comprising a cross-sectionally concavoconvex body of flexible material for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and upper eyelid in generally radially spaced relation to the cornea of the eyeball and in the path of flow of tears from the associated lacrimal gland, said body having a curved outline and an inner concave surface, said concave surface having a generally spherical radius substantially equal to that of the outer scleral surface of an eyeball, and a supply of medicament contained within said body, said body being responsive to flow of tears thereover, when the body is applied to the eyeball, to dispense said medicament to the eyeball generally above the cornea, said body being so constructed and arranged that the rate of dispensing said medicament is dependent upon the rate of flow of tears over said body.
  • the medication dispensing tablet defined in claim 1 in which said body comprises a pair of inner and outer walls defining a chamber for the medicament, said body having multiple perforations through at least one of said walls, whereby the medicament in said chamber seeps outwardly fro-m said chamber into the tear flow over said body 5.
  • the medication dispensing tablet defined in claim 1 characterized by dye in said medicament for visual indication of the presence of medicament in said body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)

Description

Dec. 17, 1968 R. A. NESS 3,416,530
EYEBALL MEDICATION DISPENSING TABLET Filed March 2, 1966 2 Sheets-Sheet l INVENTOR.
R/cHARo A. Nsss BY AT TORNE Y5 Dec. 17, 1968 Filed March 2, 1966 FIG. 3
R. A. NESS EYEBALL MEDICATION DISPENS ING TABLET 2 Sheets-Sheet 2 'AT TORNE Y5 United States Patent 3,416,530 EYEBALL MEDICATION DISPENSING TABLET Richard A. Ness, Fergus Falls, Minn. 56537 Filed Mar. 2, 1966, Ser. No. 531,311 7 Claims. (Cl. 128260) This invention relates generally to the treatment of disseases of the eye, and more particularly, to novel means for dispensing medication to the human eyeball.
At the present time, in the treatment of eye diseases, such as glaucoma, medication is applied to the cornea of the eye in liquid or ointment form. In many cases, to be effective, the application of medication to the cornea should be substantially continuous. Such a procedure is highly inconvenient and confining to the patient. At best, the medication is applied at intervals during the day and night. However, the difiiculty with such periodic application is that the eye receives a massive dose at the time of application, and shortly thereafter, substantially all of the medication is washed away by tears, leaving the eye, particularly the cornea thereof, without medication until the next dose is applied.
An important object of this invention is the provision of means whereby medication is applied to the eyeball continuously over an extended period of time.
Another object of this invention is the provision of a medication dispensing device which may be quickly and easily applied to the eyeball, which will dispense medication thereto-at a predetermined rate of speed, and which may be as quickly and easily removed and replaced when the supply of medicament is exhausted.
Still another object of this invention is the provision of a medication dispensing device having means providing a visual indication of the quantity of medicament available to the eyeball.
Yet another object of this invention is the provision of a medication dispensing device which will conform to the curvature of the sclera so as to fit comfortably in the culde-sac of the conjunctiva between the upper eyelid and the eyeball or globe in radially spaced relation to the cornea, and disposed in the path of tear flow to the cornea, whereby to be responsive to flow of tears to dispense medicament thereto.
To the above ends, I provide a medication dispensing tablet-like body of concavo-convex section and of flexible material and having a smooth curved outline, the concave inner surface of said body having a generally spherical radius conforming substantially to the radius of the scleral portion of an eyeball, the body containing a supply of medicament and adapted to dispense the medicament to tears during flow of said tears from the lacrimal gland toward the cornea of the eyeball, when the body is applied to the eyeball as set forth. The above, and still further highly important objects and advantages of this invention will become apparent from the following detailed specification, appended cl-aims and attached drawings.
Referring to the drawings, which illustrate the invention, and in which like reference characters indicate like parts throughout the several views:
FIG. 1 is a view partly in front elevation and partly diagrammatic, of a human eye, illustrating the use of the invention;
FIG. 2 is a view partly in vertical section and partly diagrammatic of an eyeball and the upper and lower eyelids associated therewith, showing the placement of the medication dispensing tablet of this invention;
FIG. 3 is a view in top plan of a preferred form of medication dispensing tablet of this invention;
FIG. 4 is a longitudinal section, taken on the line 44 of FIG. 3;
FIG. 5 is a transverse section taken substantially on the line 5-5 of FIG. 3;
FIG. 6 is a view corresponding ot FIG. 3 but showing a modified form of tablet;
FIG. 7 is a view in perspective of means for packaging the tablet of this invention; and
FIG. 8 is an enlarged transverse section, taken on the line 88 of FIG. 7.
Referring particularly to FIGS. 1 and 2, a human eye is shown, more or less diagrammatically, as comprising an eyeball 1, and upper and lower eyelids 2 and 3 respectively, the eyeball 1 being covered for the greater parts of its area by the sclera 4 and at its anterior portion by the cornea 5. The eyelids 2 and 3 are lined with a epithelial membrane or conjunctiva 6 which covers the exposed portion of the eyeball including the cornea 5, that portion covering the cornea being transparent, that portion of the conjunctiva 6 which lines the upper eyelid 2 and the underlying portion of the sclera 4 defining a cul-de-sac 7. Upper and lower eyelashes are indicated at 8 and 9 respectively. Other details of the structure of the eyeball 1 are not directly concerned with the structure of the instant invention, detailed showing and description thereof being omitted in the interest of brevity. The usual lacrimal gland associated with the eyeball 1 is shown by dot and dash lines in FIG. 1 and indicated by the numeral 10.
The preferred embodiment of the invention illustrated in FIGS. l-S, a hollow tablet-like body 11, of concavoconvex cross section, is shown as comprising inner and outer walls 12 and 13 respectively, the walls 12 and 13 being joined at their marginal edge portions and defining a chamber 14 that is filled with medicament 15. The marginal juncture of the walls 12 and 13 is rounded, as indicated at 16 in FIGS. 4 and 5, so as to avoid sharp edges and, in the preferred embodiment of the invention, the
outline of the body 11 is bean-shaped or reniform as shown in FIGS. 1 and 3. Communication between the chamber 14 and the exterior of the body 11 is had through a plurality of capillary openings 17 in the walls 12 and 13, as well as through the joined edges thereof. The marginal edges of the inner and outer walls 12 and 13 may be joined together by any suitable means, such as heat-sealing, gluing or the like. Preferably, the capillary openings 17 are disposed in the areas of the walls 12 and 13 adjacent the marginal edges thereof as shown particularly in FIG. 3.
In order that the body 11 may comfortably fit in the cul-de-sac 7, the overall dimensions of the body 11 are quite small. Preferably, the overall length of the body 11 is approximately fifteen millimeters, the width thereof intermediate its ends being in the neighborhood of eleven or twelve millimeters. The outer surface 18, which is adapted to be disposed adjacent the sclera, of the inner wall 12 is generally spherical, having a spherical radius of approximately twelve millimeters, corresponding to the radius of the scleral portion of the eyeball. Obviously, the dimensions noted above may be varied in accordance with eyeballs of different sizes. It will be noted, with reference to FIGS. 4 and 5, that the body 11 is of substantially greater thickness at its central portion than at the marginal edge thereof, whereby to define a chamber 14 of a :size to contain sufiicient highly concentrated medication for adequate treatment over at least a days time. Preferably, the maximum thickness of the body 11 is approximately one to one and one-half millimeters. When the body 11, filled with medicament 15, is placed in the cul-de-sac 7, some of the tear liquid flowing from the lacrimal gland 10 to and across the eyeball 1 will enter the chamber 14 through some of the capillary openings 17, and outwardly therefrom through others of the openings 17, carrying with it some of the medicament 15. Responsive to blinking action of the upper eyelid 2, the tear liquid and medicament mixture will flow over the cornea 5 which absorbs the medicament, thus administering a constant supply of medicament to the cornea until the supply within the chamber 14 is exhausted. Normally, the lacrimal gland is disposed just slightly above and posteriorly or rearwardly of the cul-de-sac 7 in a depression of the upper, outer wall of the orbit, not shown. The flow of tears from the lacrimal gland 10 is generally diagonally across the cornea toward the puncta, as is wellknown to those skilled in this art, the general direction of tear flow being indicated by arrows in FIG. 1.
The tablet-like body 11 may be made from any suitable material that is flexible, biologically inert, nonellergenic, insoluble in tear liquid, and chemically compatible with the medicament in the chamber 14. The walls 12 and 13 of the body 11 may be made from polyethylene or any other of well-known synthetic plastic materials having the above-mentioned characteristics. The medicament in the chamber 14 comprises the desired medication for treatment and a soluble or semi-soluble carrier or matrix, the matrix being of any suitable substance such as gum acacia, gum tragacanth, or the like. The matrix serves to hold the medication together during fabrication of the body 11, and operates as a diluent during the medication dispensing operation of the body 11.
Insertion of the body 11 into the cul-de-sac 7 and removal of the body 11 therefrom is a relatively simple and easy operation. The body 11 may be mounted on or grasped by a suitable tool or holder, not shown, but which may include a minute suction cup for engaging the outer Wall of the body 11. The upper eyelid is raised upwardly and outwardly adjacent the outer corner portion of the eye to open the cul-de-sac 7, and the body 11 inserted and released from the holder. The holder may be one of several types commonly used to insert and remove present day corneal contact lenses, artificial eyes and the like.
The present invention contemplates the use of an indicator dye in the medicament 15 to serve as a visual indication as to the supply of medicament within the chamber 14. For this purpose, a small amount of methylene blue or any suitable dye material is used. So that the medicament 15 may be easily seen, the outer wall 13 of the body 11 is preferably transparent, the inner wall 12 being preferably opaque and having a color in substantial contrast to the color of the medicament 15 or indicator dye.
The modified form of the invention illustrated in FIG. 6 comprises a body 19 that is generally elliptical in outline but which in all other respects is identical to the form of body 11 illustrated in FIGS. 1-5. The parts of the body 19 shown in FIG. 6, corresponding to similar parts of the body 11, are indicated by corresponding reference numerals with prime marks added. Thus the outer wall 13 and the marginal edge 16' are provided with capillary openings 17' and it may be assumed that the body 19 is cross-sectionally similar to the body 11, as shown in FIGS. 4 and 5.
A preferred means for packaging the tablets of this invention is shown in FIGS. 7 and 8. A relatively thick sheet-like base member 20 is shown as being formed to provide a plurality of upwardly opening pockets 21, each for reception of a different one of the tablets of bodies 11 or 19, and having upwardly dished bottom walls 22 which substantially fit the overlying inner wall-s of the bodies 11 or 19. A relatively thin cover sheet 23 overlies the base member 20 and is releasably adhered to the top surface thereof intermediate the pockets 21 and adjacent the marginal edge of the base member 20. Preferably, the base member 20 and cover sheet 23 are made from synthetic plastic sheet material, the cover sheet 23 being preferably transparent so that occupancy of any of the pockets 21 by a tablet may be readily seen. Further, when packaging the tablets, it is desirable to introduce a small amount of the medicament into the various pockets 21 to maintain the outer surfaces of the tablets or bodies 11 or 19 in a moist condition for ease of application to the eyeball. Preferably, the upper surfaces of the base member 20 in the pockets 21 are corrugated, knurled, or otherwise roughened, as indicated at 21a, to prevent the liquid in the pockets 21 from causing the bodies 11 to adhere to the pockets 21, and to break any suction therebetween, which might occur if the surfaces of the pockets 21 were smooth.
It will be appreciated that the outline of the tablets 11 or 19 may be of any curved configuration, such as circular, if desired. Further, the capillary openings 17 and 17 need not be necessarily circular as shown. If desired, the walls 12, 13, 12' and 13 may be made from porous material having the characteristics above described in connection with the body 11. Still further, this invention contemplates a body of the shape or shapes above described, which in itself is a solid body, as distinguished from the bodies 11 or 19 which define inner chambers, but which is in itself sufficiently porous to receive the desired amount of medicament and retain the same until the medicament is gradually leached therefrom under the action of tear flow. In such a modification, the body, not shown, may be made from suitable material of a given color, the medication being dyed to a contrasting color, whereby to provide an indication as to the presence or absence of medication in the porous body.
While I have shown and described a preferred form and a single modification of medication dispensing tablet, it will be understood that the same may be produced in other different shapes, such as circular, and that other modifications may be made without departure from the spirit and scope of the invention, as defined in the claims.
What is claimed is:
1. A medication dispensing tablet for a human eyeball, said tablet comprising a cross-sectionally concavoconvex body of flexible material for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and upper eyelid in generally radially spaced relation to the cornea of the eyeball and in the path of flow of tears from the associated lacrimal gland, said body having a curved outline and an inner concave surface, said concave surface having a generally spherical radius substantially equal to that of the outer scleral surface of an eyeball, and a supply of medicament contained within said body, said body being responsive to flow of tears thereover, when the body is applied to the eyeball, to dispense said medicament to the eyeball generally above the cornea, said body being so constructed and arranged that the rate of dispensing said medicament is dependent upon the rate of flow of tears over said body.
2. The medication dispensing tablet defined in claim 1 in which the marginal outline of said body is generally elliptical.
3. The medication dispensing tablet defined in claim 1 in which the marginal outline of said boy is generally bean-shaped.
4. The medication dispensing tablet defined in claim 1 in which said body comprises a pair of inner and outer walls defining a chamber for the medicament, said body having multiple perforations through at least one of said walls, whereby the medicament in said chamber seeps outwardly fro-m said chamber into the tear flow over said body 5. The medication dispensing tablet defined in claim 1 characterized by dye in said medicament for visual indication of the presence of medicament in said body.
5 6 6. The medication dispensing tablet defined in claim References Cited f! which tthe 03ml Of Of saiddbodayl UNITED STATES PATENTS 1s ransparen, 5211 me icarnen incu ing a me 1cm agent and a soluble matrix, characterized by a dye of a 772,028 10/1904 Carpenter 128-260 given color in said medicament, for visual indication of 5 32? 52223;
the presence of medicament in said chamber.
7. The medication dispensing tablet defined in claim 6 l 4 in which the inner one of the Walls of said body is dyed ADELE EAGER Puma), Exammer' to a given color, the dye in said medicament being of a U S C1 X R color substantially different from that of the colored inner 10 Wall. 128261, 268; 16759; 20663.2

Claims (1)

1. A MEDICIATION DISPENSING TABLET FOR A HUMAN EYE BALL, SAID TABLET COMPRISING A CROSS-SECTIONALLY CONCAVOCONVEX BODY OF FLEXIBLE MATERIAL FOR INSERTION INTO THE CUL-DE-SAC OF THE CONJUNCTIVA BETWEEN THE SCLERA OF THE EYEBALL AND UPPER EYELID IN GENERALLY RADIALLY SPACED RELATION TO THE CORNEA OF THE EYEBALL AND IN THE PATH OF FLOW OF TEARS FROM THE ASSOCIATED LACRIMAL GLAND, SAID BODY HAVING A CURVED OUTLINE AND AN INNER CONCAVE SURFACE, SAID CONCAVE SURFACE HAVING A GENERALLY SPHERICAL RADIUS SUBSTANTIALLY EQUAL TO THAT OF THE OUTER SCLERAL SURFACE OF AN EYEBALL, AND A SUPPLY OF MEDICAMENT CONTAINED WITHIN SAID BODY, SAID BODY BEING RESPONSIVE TO FLOW OF
US531311A 1966-03-02 1966-03-02 Eyeball medication dispensing tablet Expired - Lifetime US3416530A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US531311A US3416530A (en) 1966-03-02 1966-03-02 Eyeball medication dispensing tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US531311A US3416530A (en) 1966-03-02 1966-03-02 Eyeball medication dispensing tablet

Publications (1)

Publication Number Publication Date
US3416530A true US3416530A (en) 1968-12-17

Family

ID=24117121

Family Applications (1)

Application Number Title Priority Date Filing Date
US531311A Expired - Lifetime US3416530A (en) 1966-03-02 1966-03-02 Eyeball medication dispensing tablet

Country Status (1)

Country Link
US (1) US3416530A (en)

Cited By (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3626940A (en) * 1969-05-02 1971-12-14 Alza Corp Ocular insert
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
DE2243986A1 (en) * 1971-09-09 1973-03-29 Alza Corp BIODEGRADABLE EYE INSERT FOR ADMINISTRATION OF A MEDICINAL PRODUCT
US3814097A (en) * 1972-02-14 1974-06-04 Ici Ltd Dressing
US3826258A (en) * 1972-02-07 1974-07-30 S Abraham Gradual release medicine carrier
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3853116A (en) * 1971-06-21 1974-12-10 Investors In Ventures Inc Implant methods and devices for influencing body fluids
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
USB520277I5 (en) * 1971-09-09 1976-02-17
DE2547378A1 (en) * 1974-10-24 1976-04-29 Searle & Co DEVICE WITH LOCKED MICROCHAMBERS FOR DISPENSING A MEDICINAL PRODUCT
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136178A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4201210A (en) * 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
US4304226A (en) * 1980-03-03 1981-12-08 The Procter & Gamble Company Vaginal contraceptive
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
WO1993007840A1 (en) * 1991-10-15 1993-04-29 Advanced Corneal Systems, Inc. Enzyme-orthokeratology
WO1993019707A1 (en) * 1992-04-02 1993-10-14 Bausch & Lomb Incorporated Ophthalmic article
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5472436A (en) * 1994-07-26 1995-12-05 Fremstad; Daria A. Ocular appliance for delivering medication
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5788957A (en) * 1991-10-15 1998-08-04 Advanced Corneal Systems, Inc. Enzyme-orthokeratology
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6161544A (en) * 1998-01-28 2000-12-19 Keratoform, Inc. Methods for accelerated orthokeratology
WO2001030323A2 (en) * 1999-10-22 2001-05-03 Oculex Pharmaceuticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2001032140A1 (en) 1999-11-04 2001-05-10 Btg Int Ltd Ocular insert
US6303102B1 (en) 2000-09-07 2001-10-16 Kenneth Schlichte Cutaneously applied biodegradable tell-tale having controllable clearing time
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6413540B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device
US6413245B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20020106395A1 (en) * 2001-01-03 2002-08-08 Brubaker Michael J. Sustained release drug delivery devices with prefabricated permeable plugs
US20020110635A1 (en) * 2001-01-26 2002-08-15 Brubaker Michael J. Process for the production of sustained release drug delivery devices
US20020188282A1 (en) * 2001-02-13 2002-12-12 Robert Greenberg Implantable drug delivery device
US20030176854A1 (en) * 2002-03-11 2003-09-18 Alcon, Inc. Implantable drug delivery system
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20040092911A1 (en) * 2001-07-23 2004-05-13 Yoseph Yaacobi Ophthalmic drug delivery device
US6756058B2 (en) 2001-01-03 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices with multiple agents
US6756049B2 (en) 2000-12-29 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices
US20040133155A1 (en) * 2000-08-30 2004-07-08 Varner Sign Erickson Devices for intraocular drug delivery
US20050013845A1 (en) * 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
US20050019371A1 (en) * 2003-05-02 2005-01-27 Anderson Aron B. Controlled release bioactive agent delivery device
US20060039952A1 (en) * 2003-07-10 2006-02-23 Yoseph Yaacobi Ophthalmic drug delivery device
US20060067966A1 (en) * 1995-06-02 2006-03-30 Allergan, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US7094226B2 (en) 2001-07-23 2006-08-22 Alcon, Inc. Ophthalmic drug delivery device
US20060210604A1 (en) * 2004-10-04 2006-09-21 Eric Dadey Ocular delivery of polymeric delivery formulations
US20060270968A1 (en) * 2003-03-21 2006-11-30 Robert Greenberg Transretinal implant and method of manufacture
US20070092570A1 (en) * 1999-10-21 2007-04-26 Missel Paul J Drug delivery device
US20070112318A1 (en) * 2003-08-26 2007-05-17 Leahy Charles D Ocular drug delivery device
US20070244442A1 (en) * 2004-12-22 2007-10-18 Chowhan Masood A Device for Ophthalmic Drug Delivery
US20070280992A1 (en) * 2004-10-04 2007-12-06 Qlt Usa, Inc. Sustained delivery formulations of rapamycin compounds
US20070298074A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20090093788A1 (en) * 2007-10-09 2009-04-09 Alcon Research, Ltd. Thermal Coefficient Driven Drug Pellet Size For Ophthalmic Injection
US20090093789A1 (en) * 2007-10-09 2009-04-09 Alcon Research, Ltd. Method of Delivering A Rate And Temperature - Dependent Substance Into The Eye
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20100004609A1 (en) * 2008-07-03 2010-01-07 Michael Campion Eye coloring systems
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20100226962A1 (en) * 2009-03-03 2010-09-09 Rodstrom Theron R Peri-corneal drug delivery device
WO2010147653A1 (en) 2009-06-16 2010-12-23 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US20110028807A1 (en) * 1996-09-04 2011-02-03 Marcio Marc Abreu Contact lens for collecting tears and detecting at least one analyte
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
EP2329821A1 (en) 2005-11-29 2011-06-08 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
US20110184358A1 (en) * 2010-01-27 2011-07-28 Weiner Alan L Pulsatile peri-corneal drug delivery device
US8034366B2 (en) 2003-01-09 2011-10-11 Allergan, Inc. Ocular implant made by a double extrusion process
EP2374451A2 (en) 2005-07-27 2011-10-12 University of Florida Research Foundation, Inc. Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
US20120078362A1 (en) * 2009-05-18 2012-03-29 Dose Medical Corporation Drug eluting ocular implant
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8242099B2 (en) 2000-07-05 2012-08-14 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
WO2012174064A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8367097B2 (en) 2005-02-09 2013-02-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
WO2013058809A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8486052B2 (en) 2001-06-12 2013-07-16 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8765166B2 (en) 2010-05-17 2014-07-01 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US8802129B2 (en) 2004-04-30 2014-08-12 Allergan, Inc. Methods for treating retinopathy with extended therapeutic effect
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
JP5671183B1 (en) * 2014-08-28 2015-02-18 株式会社ユニバーサルビュー Eyelid interior tools
WO2015071427A1 (en) 2013-11-14 2015-05-21 Eyed Pharma Eye device
US9102105B2 (en) 2011-09-13 2015-08-11 Vista Scientific Llc Method for forming an ocular drug delivery device
EP2944628A1 (en) 2011-11-30 2015-11-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US20180092771A1 (en) * 2013-11-04 2018-04-05 Vance M. Thompson Conjunctival cover and methods therefor
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP6473915B1 (en) * 2018-03-30 2019-02-27 真一 芦田 Ophthalmic device, drug supply ophthalmic device, and ophthalmic attachment
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
WO2019136358A1 (en) * 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US10485701B2 (en) 2002-04-08 2019-11-26 Glaukos Corporation Devices and methods for glaucoma treatment
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10596330B2 (en) 2015-08-26 2020-03-24 Medtronic Xomed, Inc. Resorbable, drug-eluting submucosal turbinate implant device and method
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
USD901683S1 (en) 2017-10-27 2020-11-10 Glaukos Corporation Implant delivery apparatus
US10828473B2 (en) 2001-04-07 2020-11-10 Glaukos Corporation Ocular implant delivery system and methods thereof
US10828195B2 (en) 2006-11-10 2020-11-10 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2021081117A2 (en) 2019-10-24 2021-04-29 Labombard Denis E Ocular device and drug delivery system, with case
US11116625B2 (en) 2017-09-28 2021-09-14 Glaukos Corporation Apparatus and method for controlling placement of intraocular implants
US11197780B2 (en) 2012-03-26 2021-12-14 Glaukos Corporation System and method for delivering multiple ocular implants
US11224602B2 (en) 2015-04-13 2022-01-18 Forsight Vision5, Inc. Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US11281023B2 (en) 2016-10-17 2022-03-22 Tearoptix, Inc. Tear shaping for refractive correction
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11376040B2 (en) 2017-10-06 2022-07-05 Glaukos Corporation Systems and methods for delivering multiple ocular implants
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11559430B2 (en) 2013-03-15 2023-01-24 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US11567348B2 (en) 2015-03-11 2023-01-31 Tearoptix, Inc. Tear shaping for refractive correction
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2023073706A1 (en) 2021-10-27 2023-05-04 Avisi Ltd. Ophthalmic device
US11703695B2 (en) 2018-04-06 2023-07-18 Tearoptix, Inc. Tear shaping for refractive correction
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
WO2024224394A1 (en) 2023-04-27 2024-10-31 Avisi Ltd. Elastomeric matrices comprising polyvinyl alcohol

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US772028A (en) * 1903-11-13 1904-10-11 George A Carpenter Device for putting medicine into eyes.
US2347488A (en) * 1943-04-05 1944-04-25 John H Lawior Optical lens
US3302646A (en) * 1964-01-10 1967-02-07 Charles A Behney Apparatus for treating eye infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US772028A (en) * 1903-11-13 1904-10-11 George A Carpenter Device for putting medicine into eyes.
US2347488A (en) * 1943-04-05 1944-04-25 John H Lawior Optical lens
US3302646A (en) * 1964-01-10 1967-02-07 Charles A Behney Apparatus for treating eye infection

Cited By (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626940A (en) * 1969-05-02 1971-12-14 Alza Corp Ocular insert
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3853116A (en) * 1971-06-21 1974-12-10 Investors In Ventures Inc Implant methods and devices for influencing body fluids
USB520277I5 (en) * 1971-09-09 1976-02-17
US3995635A (en) * 1971-09-09 1976-12-07 Alza Corporation Ocular insert
DE2243986A1 (en) * 1971-09-09 1973-03-29 Alza Corp BIODEGRADABLE EYE INSERT FOR ADMINISTRATION OF A MEDICINAL PRODUCT
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3826258A (en) * 1972-02-07 1974-07-30 S Abraham Gradual release medicine carrier
US3814097A (en) * 1972-02-14 1974-06-04 Ici Ltd Dressing
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2547378A1 (en) * 1974-10-24 1976-04-29 Searle & Co DEVICE WITH LOCKED MICROCHAMBERS FOR DISPENSING A MEDICINAL PRODUCT
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4201210A (en) * 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4136178A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
US4304226A (en) * 1980-03-03 1981-12-08 The Procter & Gamble Company Vaginal contraceptive
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
WO1993007840A1 (en) * 1991-10-15 1993-04-29 Advanced Corneal Systems, Inc. Enzyme-orthokeratology
US5626865A (en) * 1991-10-15 1997-05-06 Advanced Corneal Systems, Inc. Enzyme-orthokeratology
US6132735A (en) * 1991-10-15 2000-10-17 Ista Pharmaceutical, Inc. Enzyme-orthokeratology
US5788957A (en) * 1991-10-15 1998-08-04 Advanced Corneal Systems, Inc. Enzyme-orthokeratology
WO1993019707A1 (en) * 1992-04-02 1993-10-14 Bausch & Lomb Incorporated Ophthalmic article
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5472436A (en) * 1994-07-26 1995-12-05 Fremstad; Daria A. Ocular appliance for delivering medication
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US20060067966A1 (en) * 1995-06-02 2006-03-30 Allergan, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US20110028807A1 (en) * 1996-09-04 2011-02-03 Marcio Marc Abreu Contact lens for collecting tears and detecting at least one analyte
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6161544A (en) * 1998-01-28 2000-12-19 Keratoform, Inc. Methods for accelerated orthokeratology
US20040131655A1 (en) * 1999-10-21 2004-07-08 Yoseph Yaacobi Ophthalmic drug delivery device
US20040131654A1 (en) * 1999-10-21 2004-07-08 Yoseph Yaacobi Ophthalmic drug delivery device
US20070092570A1 (en) * 1999-10-21 2007-04-26 Missel Paul J Drug delivery device
US6413540B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device
US6413245B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20050112175A1 (en) * 1999-10-21 2005-05-26 Yoseph Yaacobi Drug delivery device
US6808719B2 (en) 1999-10-21 2004-10-26 Alcon, Inc. Drug delivery device
US7943162B2 (en) 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6669950B2 (en) 1999-10-21 2003-12-30 Alcon, Inc. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2001030323A3 (en) * 1999-10-22 2002-02-21 Oculex Pharm Inc Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2001030323A2 (en) * 1999-10-22 2001-05-03 Oculex Pharmaceuticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6264971B1 (en) * 1999-11-04 2001-07-24 Btg International Limited Ocular insert
WO2001032140A1 (en) 1999-11-04 2001-05-10 Btg Int Ltd Ocular insert
US9789001B2 (en) 2000-04-14 2017-10-17 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US8348877B2 (en) 2000-04-14 2013-01-08 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US9066782B2 (en) 2000-04-14 2015-06-30 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
EP1982701A2 (en) 2000-04-26 2008-10-22 pSivida Inc Sustained Release Drug Delivery Devices, Methods of Use, and Methods of Manufacturing Thereof
US10206934B2 (en) 2000-07-05 2019-02-19 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US9012437B2 (en) 2000-07-05 2015-04-21 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US8242099B2 (en) 2000-07-05 2012-08-14 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US9775849B2 (en) 2000-07-05 2017-10-03 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US20040133155A1 (en) * 2000-08-30 2004-07-08 Varner Sign Erickson Devices for intraocular drug delivery
US8096972B2 (en) 2000-08-30 2012-01-17 Johns Hopkins University Devices for intraocular drug delivery
US6303102B1 (en) 2000-09-07 2001-10-16 Kenneth Schlichte Cutaneously applied biodegradable tell-tale having controllable clearing time
US20040137034A1 (en) * 2000-11-29 2004-07-15 Wong Vernon G. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7846468B2 (en) 2000-11-29 2010-12-07 Allergan, Inc. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US8828446B2 (en) 2000-11-29 2014-09-09 Allergan, Inc. Method for reducing transplant rejection in the eye and intraocular implants for use therefor
US8043628B2 (en) 2000-11-29 2011-10-25 Allergan, Inc. Methods for reducing edema
US9592242B2 (en) 2000-11-29 2017-03-14 Allergan, Inc. Methods for treating edema in the eye and intraocular implants for use therefor
US7033605B2 (en) 2000-11-29 2006-04-25 Allergan, Inc. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US8088407B2 (en) 2000-11-29 2012-01-03 Allergan, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7767223B2 (en) 2000-11-29 2010-08-03 Allergan, Inc. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
US20060198871A1 (en) * 2000-11-29 2006-09-07 Allergan, Inc. Methods for treating neovascularization and intravitreal implants
US9283178B2 (en) 2000-11-29 2016-03-15 Allergan, Inc. Methods for treating edema in the eye and intraocular implants for use therefor
US8071120B2 (en) 2000-11-29 2011-12-06 Allergan, Inc. Methods for treating neovascularization and intravitreal implants
US20050249710A1 (en) * 2000-11-29 2005-11-10 Allergan, Inc. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7625582B2 (en) 2000-11-29 2009-12-01 Allergan, Inc. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20040208909A1 (en) * 2000-12-29 2004-10-21 Brubaker Michael J Sustained release drug delivery devices
US6756049B2 (en) 2000-12-29 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices
US6964781B2 (en) 2001-01-03 2005-11-15 Bausch & Lomb Incorporated Sustained release drug delivery devices with prefabricated permeable plugs
US20020106395A1 (en) * 2001-01-03 2002-08-08 Brubaker Michael J. Sustained release drug delivery devices with prefabricated permeable plugs
US6756058B2 (en) 2001-01-03 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices with multiple agents
US20020110635A1 (en) * 2001-01-26 2002-08-15 Brubaker Michael J. Process for the production of sustained release drug delivery devices
US20060062826A1 (en) * 2001-01-26 2006-03-23 Brubaker Michael J Process for the production of sustained release drug delivery devices
US6991808B2 (en) 2001-01-26 2006-01-31 Bausch & Lomb Inc. Process for the production of sustained release drug delivery devices
US7181287B2 (en) 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US20070026048A1 (en) * 2001-02-13 2007-02-01 Robert Greenberg Implantable drug delivery device
US7527621B2 (en) 2001-02-13 2009-05-05 Second Sight Medical Products, Inc. Implantable drug delivery device
US20020188282A1 (en) * 2001-02-13 2002-12-12 Robert Greenberg Implantable drug delivery device
US10828473B2 (en) 2001-04-07 2020-11-10 Glaukos Corporation Ocular implant delivery system and methods thereof
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US10470924B2 (en) 2001-06-12 2019-11-12 The Johns Hopkins University Reservoir device for intraocular drug delivery
US9522082B2 (en) 2001-06-12 2016-12-20 The Johns Hopkins University Reservoir device for intraocular drug delivery
US9180046B2 (en) 2001-06-12 2015-11-10 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US8486052B2 (en) 2001-06-12 2013-07-16 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US7094226B2 (en) 2001-07-23 2006-08-22 Alcon, Inc. Ophthalmic drug delivery device
US6986900B2 (en) 2001-07-23 2006-01-17 Alcon, Inc. Ophthalmic drug delivery device
US20040092911A1 (en) * 2001-07-23 2004-05-13 Yoseph Yaacobi Ophthalmic drug delivery device
US7621907B2 (en) 2002-03-11 2009-11-24 Alcon, Inc. Implantable drug delivery system
US20100022945A1 (en) * 2002-03-11 2010-01-28 Theron Robert Rodstrom Implantable drug delivery system
US20030176854A1 (en) * 2002-03-11 2003-09-18 Alcon, Inc. Implantable drug delivery system
US10485701B2 (en) 2002-04-08 2019-11-26 Glaukos Corporation Devices and methods for glaucoma treatment
US20080268021A1 (en) * 2002-11-12 2008-10-30 Qlt Usa, Inc. Adhesive bioerodible ocular drug delivery system
US20050013845A1 (en) * 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
US9192511B2 (en) 2003-01-09 2015-11-24 Allergan, Inc. Ocular implant made by a double extrusion process
US8318070B2 (en) 2003-01-09 2012-11-27 Allergan, Inc. Ocular implant made by a double extrusion process
US8034366B2 (en) 2003-01-09 2011-10-11 Allergan, Inc. Ocular implant made by a double extrusion process
US8034370B2 (en) 2003-01-09 2011-10-11 Allergan, Inc. Ocular implant made by a double extrusion process
US10702539B2 (en) 2003-01-09 2020-07-07 Allergan, Inc. Ocular implant made by a double extrusion process
US10076526B2 (en) 2003-01-09 2018-09-18 Allergan, Inc. Ocular implant made by a double extrusion process
US8778381B2 (en) 2003-01-09 2014-07-15 Allergan, Inc. Ocular implant made by a double extrusion process
US8506987B2 (en) 2003-01-09 2013-08-13 Allergan, Inc. Ocular implant made by a double extrusion process
US20060270968A1 (en) * 2003-03-21 2006-11-30 Robert Greenberg Transretinal implant and method of manufacture
US9993367B2 (en) 2003-03-21 2018-06-12 Second Sight Medical Products, Inc. Transretinal implant and method of manufacture
US7824704B2 (en) 2003-05-02 2010-11-02 Surmodics, Inc. Controlled release bioactive agent delivery device
US20050019371A1 (en) * 2003-05-02 2005-01-27 Anderson Aron B. Controlled release bioactive agent delivery device
US8034369B2 (en) 2003-05-02 2011-10-11 Surmodics, Inc. Controlled release bioactive agent delivery device
US8021680B2 (en) 2003-05-02 2011-09-20 Surmodics, Inc. Controlled release bioactive agent delivery device
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US7976862B2 (en) 2003-05-02 2011-07-12 Surmodics, Inc. Controlled release bioactive agent delivery device
US20060039952A1 (en) * 2003-07-10 2006-02-23 Yoseph Yaacobi Ophthalmic drug delivery device
US8287504B2 (en) 2003-08-26 2012-10-16 Vista Scientific Llc Ocular drug delivery device
US8679078B2 (en) 2003-08-26 2014-03-25 Vista Scientific Llc Ocular drug delivery device
US8167855B2 (en) 2003-08-26 2012-05-01 Vista Scientific Llc Ocular drug delivery device
US20100331796A1 (en) * 2003-08-26 2010-12-30 Vista Scientific Llc Ocular drug delivery device
US20070112318A1 (en) * 2003-08-26 2007-05-17 Leahy Charles D Ocular drug delivery device
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US9233071B2 (en) 2004-04-30 2016-01-12 Allergan, Inc. Methods for treating retinopathy with extended therapeutic effect
US8911768B2 (en) 2004-04-30 2014-12-16 Allergan, Inc. Methods for treating retinopathy with extended therapeutic effect
US8802129B2 (en) 2004-04-30 2014-08-12 Allergan, Inc. Methods for treating retinopathy with extended therapeutic effect
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US20070280992A1 (en) * 2004-10-04 2007-12-06 Qlt Usa, Inc. Sustained delivery formulations of rapamycin compounds
US20060210604A1 (en) * 2004-10-04 2006-09-21 Eric Dadey Ocular delivery of polymeric delivery formulations
US20070244442A1 (en) * 2004-12-22 2007-10-18 Chowhan Masood A Device for Ophthalmic Drug Delivery
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US9387165B2 (en) 2005-02-09 2016-07-12 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8927005B2 (en) 2005-02-09 2015-01-06 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8367097B2 (en) 2005-02-09 2013-02-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US9381153B2 (en) 2005-02-09 2016-07-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP2374451A2 (en) 2005-07-27 2011-10-12 University of Florida Research Foundation, Inc. Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
EP2329821A1 (en) 2005-11-29 2011-06-08 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
US8658667B2 (en) 2006-02-09 2014-02-25 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US9452156B2 (en) 2006-03-23 2016-09-27 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8486960B2 (en) 2006-03-23 2013-07-16 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298074A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US10828195B2 (en) 2006-11-10 2020-11-10 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US20090093788A1 (en) * 2007-10-09 2009-04-09 Alcon Research, Ltd. Thermal Coefficient Driven Drug Pellet Size For Ophthalmic Injection
US20090093789A1 (en) * 2007-10-09 2009-04-09 Alcon Research, Ltd. Method of Delivering A Rate And Temperature - Dependent Substance Into The Eye
US8382725B2 (en) * 2008-07-03 2013-02-26 Michael Campion Eye coloring systems
US20100004609A1 (en) * 2008-07-03 2010-01-07 Michael Campion Eye coloring systems
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US8298578B2 (en) 2009-01-29 2012-10-30 Forsight Vision4, Inc. Posterior segment drug delivery
US8808727B2 (en) 2009-01-29 2014-08-19 Forsight Vision4, Inc. Posterior segment drug delivery
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US8795712B2 (en) 2009-01-29 2014-08-05 Forsight Vision4, Inc. Posterior segment drug delivery
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
US20100226962A1 (en) * 2009-03-03 2010-09-09 Rodstrom Theron R Peri-corneal drug delivery device
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US11426306B2 (en) 2009-05-18 2022-08-30 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10813789B2 (en) 2009-05-18 2020-10-27 Dose Medical Corporation Drug eluting ocular implant
US20120078362A1 (en) * 2009-05-18 2012-03-29 Dose Medical Corporation Drug eluting ocular implant
US10004636B2 (en) 2009-06-03 2018-06-26 Forsight Vision5, Inc. Anterior segment drug delivery
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US10736774B2 (en) 2009-06-03 2020-08-11 Forsight Vision5, Inc. Anterior segment drug delivery
WO2010147653A1 (en) 2009-06-16 2010-12-23 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP3100723A1 (en) 2009-06-16 2016-12-07 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US8469934B2 (en) 2010-01-27 2013-06-25 Alcon Research, Ltd. Pulsatile peri-corneal drug delivery device
US20110184358A1 (en) * 2010-01-27 2011-07-28 Weiner Alan L Pulsatile peri-corneal drug delivery device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8765166B2 (en) 2010-05-17 2014-07-01 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US9937073B2 (en) 2010-06-01 2018-04-10 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8939948B2 (en) 2010-06-01 2015-01-27 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11786396B2 (en) 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2012174064A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US9102105B2 (en) 2011-09-13 2015-08-11 Vista Scientific Llc Method for forming an ocular drug delivery device
US10835416B2 (en) 2011-09-14 2020-11-17 Forsight Vision5, Inc. Ocular insert apparatus and methods
US20200038240A1 (en) * 2011-09-14 2020-02-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
WO2013058809A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2944628A1 (en) 2011-11-30 2015-11-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US10603209B2 (en) 2012-02-03 2020-03-31 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US11197780B2 (en) 2012-03-26 2021-12-14 Glaukos Corporation System and method for delivering multiple ocular implants
US11944573B2 (en) 2012-03-26 2024-04-02 Glaukos Corporation System and method for delivering multiple ocular implants
US10507309B2 (en) 2012-06-01 2019-12-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US9623215B2 (en) 2012-06-01 2017-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US10099041B2 (en) 2012-06-01 2018-10-16 Surmodics, Inc. Apparatus and methods for coating medical devices
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US10456293B2 (en) 2012-10-26 2019-10-29 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US11559430B2 (en) 2013-03-15 2023-01-24 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US11253394B2 (en) 2013-03-15 2022-02-22 Dose Medical Corporation Controlled drug delivery ocular implants and methods of using same
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US12115102B2 (en) 2013-03-28 2024-10-15 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10449086B2 (en) 2013-11-04 2019-10-22 Vance M. Thompson Conjunctival cover and methods therefor
US12076272B2 (en) 2013-11-04 2024-09-03 Tearoptix, Inc. Conjunctival cover and methods therefor
US20180092771A1 (en) * 2013-11-04 2018-04-05 Vance M. Thompson Conjunctival cover and methods therefor
US11672698B2 (en) 2013-11-04 2023-06-13 Tearoptix, Inc. Conjunctival cover and methods therefor
US10548767B2 (en) * 2013-11-04 2020-02-04 Vance M. Thompson Conjunctival cover and methods therefor
US11076985B2 (en) 2013-11-04 2021-08-03 Tearoptix, Inc. Conjunctival cover and methods therefor
EP3566693A1 (en) 2013-11-14 2019-11-13 EyeD Pharma Eye device
WO2015071427A1 (en) 2013-11-14 2015-05-21 Eyed Pharma Eye device
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US11992551B2 (en) 2014-05-29 2024-05-28 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US11337853B2 (en) 2014-07-15 2022-05-24 Forsight Vision4, Inc. Ocular implant delivery device and method
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016031535A1 (en) * 2014-08-28 2016-03-03 株式会社ユニバーサルビュー Device placed under eyelid
JP5671183B1 (en) * 2014-08-28 2015-02-18 株式会社ユニバーサルビュー Eyelid interior tools
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US12044904B2 (en) 2015-03-11 2024-07-23 Tearoptix, Inc. Tear shaping for refractive correction
US11567348B2 (en) 2015-03-11 2023-01-31 Tearoptix, Inc. Tear shaping for refractive correction
US11224602B2 (en) 2015-04-13 2022-01-18 Forsight Vision5, Inc. Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US11654250B2 (en) 2015-08-26 2023-05-23 Medtronic Xomed, Inc. Resorbable, drug-eluting submucosal turbinate implant device and method
US10596330B2 (en) 2015-08-26 2020-03-24 Medtronic Xomed, Inc. Resorbable, drug-eluting submucosal turbinate implant device and method
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US12102560B2 (en) 2016-04-05 2024-10-01 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US12105359B2 (en) 2016-10-17 2024-10-01 Tearoptix, Inc. Tear shaping for refractive correction
US11281023B2 (en) 2016-10-17 2022-03-22 Tearoptix, Inc. Tear shaping for refractive correction
US11116625B2 (en) 2017-09-28 2021-09-14 Glaukos Corporation Apparatus and method for controlling placement of intraocular implants
US11376040B2 (en) 2017-10-06 2022-07-05 Glaukos Corporation Systems and methods for delivering multiple ocular implants
USD901683S1 (en) 2017-10-27 2020-11-10 Glaukos Corporation Implant delivery apparatus
USD938585S1 (en) 2017-10-27 2021-12-14 Glaukos Corporation Implant delivery apparatus
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
CN112105320A (en) * 2018-01-05 2020-12-18 犹他大学研究基金会 Treating myopia progression
US11524032B2 (en) 2018-01-05 2022-12-13 University Of Utah Research Foundation Treatment of myopic progression
WO2019136358A1 (en) * 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression
JP6473915B1 (en) * 2018-03-30 2019-02-27 真一 芦田 Ophthalmic device, drug supply ophthalmic device, and ophthalmic attachment
JP2019176912A (en) * 2018-03-30 2019-10-17 真一 芦田 Ophthalmic device, ophthalmic medicament administration device, and ophthalmic mounted article
US11703695B2 (en) 2018-04-06 2023-07-18 Tearoptix, Inc. Tear shaping for refractive correction
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2021081117A2 (en) 2019-10-24 2021-04-29 Labombard Denis E Ocular device and drug delivery system, with case
WO2023073706A1 (en) 2021-10-27 2023-05-04 Avisi Ltd. Ophthalmic device
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
WO2024224394A1 (en) 2023-04-27 2024-10-31 Avisi Ltd. Elastomeric matrices comprising polyvinyl alcohol

Similar Documents

Publication Publication Date Title
US3416530A (en) Eyeball medication dispensing tablet
US4484922A (en) Occular device
US3995635A (en) Ocular insert
US4201210A (en) Veterinary ocular ring device for sustained drug release
US5147647A (en) Ocular insert for the fornix
US3952735A (en) Eye bandage
US5928662A (en) Ocular drug delivery device
KR101371685B1 (en) Therapeutic contact lens
US2920624A (en) Eye drop dispenser
US3618604A (en) Ocular insert
US4678466A (en) Internal medication delivery method and vehicle
US20090004244A1 (en) Iris design as a drug depot for zonal drug delivery by contact lens
US5387202A (en) Eye drop dispensing device
US3910618A (en) Contact lens applicator
JPH0614971A (en) Liquid administrator tip having pulled dosing nozzle
KR101789278B1 (en) Eyewash applicator
KR101427392B1 (en) Therapeutic contact lens
US3485244A (en) Eye applicator
US4369219A (en) Custom valved cervical cap with deformable margin
CN203220483U (en) Artificial-crystal drug releasing apparatus capable of opening by laser
US2765789A (en) Eyeshade applicator
US1929228A (en) Contact eyeglass construction
US4543949A (en) Custom valved cervical cap
EP0262893A2 (en) Ocular insert
US2347488A (en) Optical lens